| Anthony W Discipio, MD | |
|
1 Medical Center Dr, Lebanon, NH 03756-1000 | |
| (603) 650-7390 | |
| Not Available |
| Full Name | Anthony W Discipio |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 35 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063440253 | NPI | - | NPPES |
| 0RE4151 | Medicaid | VT | |
| 30009650 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 8868 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
Lehigh is one of four universities to receive funding through the Manufacturing PA Innovation Program COVID-19 Challenge supporting innovative research projects that could potentially impact Pennsylvania's pandemic response.
Regulatory and commercial considerations are the primary drivers for successful biosimilar clinical development, according to a new report from Quintiles, titled An Integrated Approach to Biosimilar Development & Commercialization. In addition, the report states that successful biosimilar companies will be those who collapse their clinical, commercial, and regulatory thinking into a streamlined cohesive function as they proceed with developing biosimilars.
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.
› Verified 4 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Lehigh is one of four universities to receive funding through the Manufacturing PA Innovation Program COVID-19 Challenge supporting innovative research projects that could potentially impact Pennsylvania's pandemic response.
Regulatory and commercial considerations are the primary drivers for successful biosimilar clinical development, according to a new report from Quintiles, titled An Integrated Approach to Biosimilar Development & Commercialization. In addition, the report states that successful biosimilar companies will be those who collapse their clinical, commercial, and regulatory thinking into a streamlined cohesive function as they proceed with developing biosimilars.
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.
› Verified 4 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Lehigh is one of four universities to receive funding through the Manufacturing PA Innovation Program COVID-19 Challenge supporting innovative research projects that could potentially impact Pennsylvania's pandemic response.
Regulatory and commercial considerations are the primary drivers for successful biosimilar clinical development, according to a new report from Quintiles, titled An Integrated Approach to Biosimilar Development & Commercialization. In addition, the report states that successful biosimilar companies will be those who collapse their clinical, commercial, and regulatory thinking into a streamlined cohesive function as they proceed with developing biosimilars.
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony W Discipio, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-7390 | Anthony W Discipio, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-7390 |
News Archive
Lehigh is one of four universities to receive funding through the Manufacturing PA Innovation Program COVID-19 Challenge supporting innovative research projects that could potentially impact Pennsylvania's pandemic response.
Regulatory and commercial considerations are the primary drivers for successful biosimilar clinical development, according to a new report from Quintiles, titled An Integrated Approach to Biosimilar Development & Commercialization. In addition, the report states that successful biosimilar companies will be those who collapse their clinical, commercial, and regulatory thinking into a streamlined cohesive function as they proceed with developing biosimilars.
Five years after diagnosis, only 40 percent of patients with locally-advanced oral cavity cancer will still be alive. The question is who is likely to live and who is likely to die? The answer to this question could not only help patients better predict the course of their disease, but could help doctors choose the most appropriate post-surgical treatments - patients at highest risk could receive the most aggressive combinations of radiation and chemotherapy.
The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.
› Verified 4 days ago
John H Sanders Jr., M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-7390 | |
Dr. Bryan Payne Stanifer, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Department Of Surgery, Lebanon, NH 03756 Phone: 603-650-8022 | |
Joseph David Phillips, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dartmouth Hitchcock - Thoracic Surgery, Lebanon, NH 03756 Phone: 603-650-2068 | |
Lawrence Joseph Dacey, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-7390 | |
Dr. Jock N Mccullough, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc - Cardiac Surgery, Lebanon, NH 03756 Phone: 603-650-7390 Fax: 603-650-6346 | |
Dr. Joseph Paul Desimone, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Cardiac Surgery, Lebanon, NH 03756 Phone: 603-650-6050 |